SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

[Rule 13d-101]

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13D-2(a)

(Amendment No. 3)*

CalciMedica, Inc. (Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

38942Q202

(CUSIP Number)

David Clark Elliot Press Deerfield Management Company, L.P. 345 Park Avenue South, 12th Floor New York, New York 10010 (212) 551-1600

With a copy to:

Jonathan D. Weiner, Esq. Mark D. Wood, Esq. Katten Muchin Rosenman LLP **50 Rockefeller Plaza** New York, New York 10020 (212) 940-8800

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 22, 2023

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box \Box .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

> (Continued on following pages) (Page 1 of 13 Pages)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAME OF REPORTING PERSONS		
	Deerfield Mgmt III, L.P.		
2	CHECK THE APPROP	RIATE BOX IF A MEMBER OF A GROUP	(a) 🗆
			(b) 🗵
3	SEC USE ONLY		
5			
4	SOURCE OF FUNDS		
	AF		
5		LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
	or 2(e)		
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	Delaware		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES	8	SHARED VOTING POWER	
BENEFICIALLY	U	Shind Fower	
OWNED BY EACH		122,419 (1)	
REPORTING	9	SOLE DISPOSITIVE POWER	
PERSON WITH		0	
*****	10	SHARED DISPOSITIVE POWER	
		122,419 (1)	
11	AGGREGATE AMOUN	IT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
12	122,419 (1)	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
12	CHECK BOX IF THE P	AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
13	PERCENT OF CLASS	REPRESENTED BY AMOUNT IN ROW (11)	
	2.22%		
14	TYPE OF REPORTING	PERSON	
	PN		
L	L		

(1) Comprised of 122,419 shares of common stock held by Deerfield Private Design Fund III, L.P.

1	NAME OF REPORTING	G PERSONS	
	Deerfield Private Design	Fund III, L.P.	
2	CHECK THE APPROPI	RIATE BOX IF A MEMBER OF A GROUP	(a) □ (b) ⊠
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	WC		
5	CHECK BOX IF DISCL or 2(e)	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	Delaware		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	8	SHARED VOTING POWER	
OWNED BY		122,419	
EACH REPORTING	9	SOLE DISPOSITIVE POWER	
PERSON		0	
WITH	10	SHARED DISPOSITIVE POWER	
		122,419	
11	AGGREGATE AMOUN	IT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	122,419		
12		GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
			_
13	PERCENT OF CLASS I	REPRESENTED BY AMOUNT IN ROW (11)	
	2.22%		
14	TYPE OF REPORTING	PERSON	
	PN		

1	NAME OF REPORTING	PERSONS	
	Deerfield Mgmt HIF, L.P		
2	CHECK THE APPROPR	RIATE BOX IF A MEMBER OF A GROUP	(a) 🗌
			(b) 🗵
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	AF		
5		OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
	or 2(e)		
6	CITIZENSHIP OR PLAC	CE OF ORGANIZATION	
	Delaware		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES	8	SHARED VOTING POWER	
BENEFICIALLY OWNED BY		1,713,873 (2)	
EACH	9	SOLE DISPOSITIVE POWER	
REPORTING PERSON	0		
WITH		0	
	10	SHARED DISPOSITIVE POWER	
		1,713,873 (2)	
11	AGGREGATE AMOUN	T BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,713,873 (2)		
12		GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
14			
13	PERCENT OF CLASS R	EPRESENTED BY AMOUNT IN ROW (11)	
	7.95%		
14	TYPE OF REPORTING	PERSON	
	PN		
	E IN		

(2) Comprised of 1,713,873 shares of common stock held by Deerfield Healthcare Innovations Fund, L.P.

1	NAME OF REPORTING	GPERSONS	
	Deerfield Healthcare Inn	ovations Fund, L.P.	
2	CHECK THE APPROPE	RIATE BOX IF A MEMBER OF A GROUP	(a) □ (b) ⊠
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	WC		
5	CHECK BOX IF DISCL or 2(e)	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	Delaware		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	8	SHARED VOTING POWER	
OWNED BY		122,419	
EACH REPORTING	9	SOLE DISPOSITIVE POWER	
PERSON		0	
WITH	10	SHARED DISPOSITIVE POWER	
		122,419	
11	AGGREGATE AMOUN	T BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	122,419		
12		GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
13	PERCENT OF CLASS F	REPRESENTED BY AMOUNT IN ROW (11)	
	2.22%		
14	TYPE OF REPORTING	PERSON	
	PN		
L	I		

1	NAME OF REPORTING	G PERSONS	
	Deerfield Mgmt, L.P.		
2	CHECK THE APPROPE	RIATE BOX IF A MEMBER OF A GROUP	(a) 🗆
			(b) 🗵
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	AF		
5	CHECK BOX IF DISCL or 2(e)	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
	01 2(9)		
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	Delaware		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES	8	SHARED VOTING POWER	
BENEFICIALLY OWNED BY		122,426 (2)	
EACH	9	132,426 (3) SOLE DISPOSITIVE POWER	
REPORTING PERSON			
WITH		0	
	10	SHARED DISPOSITIVE POWER	
		132,426 (3)	
11	AGGREGATE AMOUN	T BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	132,426 (3)		
12	CHECK BOX IF THE A	GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
13	PERCENT OF CLASS F	REPRESENTED BY AMOUNT IN ROW (11)	
14	2.40% TYPE OF REPORTING	DEDCON	
14	I I PE OF KEPOKI ING	rendun	
	PN		

(3) Comprised of 132,426 shares of common stock held by Deerfield Partners, L.P.

1	NAME OF REPORTIN	G PERSONS	
	Deerfield Partners, L.P.		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a		(a) 🗆
			(b) 🗵
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	WC		
5		LOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
	or 2(e)		
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	Delaware _		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	8	SHARED VOTING POWER	
OWNED BY		132,426	
EACH	9	SOLE DISPOSITIVE POWER	
REPORTING PERSON			
WITH		0	
	10	SHARED DISPOSITIVE POWER	
		132,426	
11	AGGREGATE AMOUN	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	132,426		
12		AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
10			
13	PERCENT OF CLASS	REPRESENTED BY AMOUNT IN ROW (11)	
	2.40%		
14	TYPE OF REPORTING	G PERSON	
	PN		

1	NAME OF REPORTING	G PERSONS	
	Deerfield Management C	Company, L.P.	
2	CHECK THE APPROPI	RIATE BOX IF A MEMBER OF A GROUP	(a) □ (b) ⊠
			(0) 🖾
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	AF		
5	CHECK BOX IF DISCL or 2(e)	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	\boxtimes
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	Delaware		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	8	SHARED VOTING POWER	
OWNED BY		377,264 (4)	
EACH REPORTING	9	SOLE DISPOSITIVE POWER	
PERSON WITH		0	
	10	SHARED DISPOSITIVE POWER	
		377,264 (4)	
11	AGGREGATE AMOUN	T BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	377,264 (4)		
12	CHECK BOX IF THE A	GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
13	PERCENT OF CLASS I	REPRESENTED BY AMOUNT IN ROW (11)	
-	6.84%		
14	TYPE OF REPORTING	PERSON	
	PN		

(4) Comprised of an aggregate of 377,264 shares of common stock held by Deerfield Partners, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P.

1	NAME OF REPORTING	GPERSONS	
	James E. Flynn		
2	CHECK THE APPROPE	RIATE BOX IF A MEMBER OF A GROUP	(a) □ (b) ⊠
			(U) 🖾
3	SEC USE ONLY		
4	SOURCE OF FUNDS		
	AF		
5	CHECK BOX IF DISCL or 2(e)	OSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)	
6	CITIZENSHIP OR PLA	CE OF ORGANIZATION	
	United States of America		
	7	SOLE VOTING POWER	
NUMBER OF		0	
SHARES BENEFICIALLY	8	SHARED VOTING POWER	
OWNED BY		377,264 (5)	
EACH REPORTING	9	SOLE DISPOSITIVE POWER	
PERSON WITH		0	
	10	SHARED DISPOSITIVE POWER	
		377,264 (5)	
11	AGGREGATE AMOUN	T BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	377,264 (5)		
12	CHECK BOX IF THE A	GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
13	PERCENT OF CLASS F	REPRESENTED BY AMOUNT IN ROW (11)	
	24.49%		
14	TYPE OF REPORTING	PERSON*	
	IN		

(5) Comprised of an aggregate of 377,264 shares of common stock held by Deerfield Partners, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III, L.P.

CUSIP No. <u>38942Q103</u>

This Amendment No. 3 (this "<u>Amendment</u>") to Schedule 13D amends the Schedule 13D filed by (i) Deerfield Mgmt III, L.P. ("<u>Deerfield Mgmt</u>"), (ii) Deerfield Private Design Fund III"), (ii) Deerfield Mgmt, L.P. ("<u>Deerfield Mgmt</u>"), (iv) Deerfield Partners, L.P. ("<u>Deerfield Partners</u>"), (v) Deerfield Mgmt HIF, L.P. ("<u>Deerfield Mgmt HIF</u>"), (vi) Deerfield Healthcare Innovations Fund, L.P. ("<u>Deerfield Mgmt HIF</u>"), (vi) Deerfield Mgmt HIF, L.P. ("<u>Deerfield Mgmt HIF</u>"), (vi) Deerfield Healthcare Innovations Fund, L.P. ("<u>Deerfield Mgmt HIF</u>"), (vi) Deerfield Mgmt HIF, Deerfield Management Company, L.P. ("<u>Deerfield Management</u>") and (viii) James E. Flynn, a natural person ("<u>Flynn</u>" and collectively with Deerfield Mgmt III, Deerfield Private Design Fund III, Deerfield Mgmt, Deerfield Mgmt No. 1 and Amendment No. 2 thereto (the "<u>Schedule 13D</u>"), with respect to the common stock of CalciMedica, Inc. (the "<u>Company</u>"). Deerfield Private Design Fund III, Deerfield Healthcare Innovations Fund and Deerfield Partners are collectively referred to herein as the "<u>Funds</u>".

Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to them in the Schedule 13D.

On March 22, 2023, the Company filed a Current Report on Form 8-K (the "<u>Merger Closing 8-K</u>"), which disclosed that, after giving effect to the Merger (as defined in the Merger Closing 8-K) and the Reverse Stock Split (as defined below), there were 5,517,754 shares of the Company's common stock outstanding. The purpose of this Amendment is to report a change in the percentage of the Company's outstanding common stock beneficially owned by the Reporting Persons as a result of a change in the number of shares of the Company's common stock outstanding. The number of shares reported in this Amendment gives effect to the 1-for-14 reverse split of the Company's common stock effected by the Company on March 17, 2023 (the "<u>Reverse Stock Split</u>").

Item 5. Interest in Securities of the Issuer.

Items 5(a), (b) and (c) of the Schedule 13D are hereby amended and restated in their entirety as follows:

(a)

(1)	Deerfield Mgmt III		
	Number of shares: Percentage of shares:	122,419 (comprised of shares held by Deerfield Private Design Fund III) 2.22%	
(2)	<u>Deerfield Private Design I</u>	Fund III	
	Number of shares: Percentage of shares:	122,419 2.22%	
(3)	<u>Deerfield Mgmt</u>		
	Number of shares: Percentage of shares:	132,426 (comprised of shares held by Deerfield Partners) 2.40%	

(4)	<u>Deerfield Partners</u> Number of shares: Percentage of shares:	132,426 2.40%
(5)	Deerfield Mgmt HIF	
	Number of shares: Percentage of shares:	122,419 (comprised of shares held by Deerfield Healthcare Innovations Fund) 2.22%
(6)	Deerfield Healthcare Inno	ovations Fund
	Number of shares: Percentage of shares:	122,419 2.22%
(7)	Deerfield Management Number of shares:	377,264 (comprised of shares held by Deerfield Private Design Fund III, Deerfield Healthcare Innovations Fund and Deerfield Partners)
	Percentage of shares:	6.84%
(8)	<u>Flynn</u>	
	Number of shares:	377,264 (comprised of shares held by Deerfield Private Design Fund III, Deerfield Healthcare Innovations Fund
	Percentage of shares:	and Deerfield Partners) 6.84%

*Percentage beneficial ownership reported herein reflects 5,517,754 shares of Common Stock outstanding, as disclosed in the Company's Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on March 22, 2023.

(b)

(1) <u>Deerfield Mgmt III</u>

Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 122,419 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 122,419

(2) <u>Deerfield Private Design Fund III</u>

Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 122,419 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 122,419

(1) Deerfield Mgmt HIF Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 122,419 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 122,419 Deerfield Healthcare Innovations Fund (1)Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 122,419 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 122,419 (3)Deerfield Mgmt Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 132,426 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 132,426 (4) **Deerfield Partners** Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 132,426 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 132,426 (3)**Deerfield Management** Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 377,264 Sole power to dispose or to direct the disposition: 0 Shared power to dispose or direct the disposition: 377,264 (6) <u>Flynn</u> Sole power to vote or direct the vote: 0 Shared power to vote or direct the vote: 377,264 Sole power to dispose or to direct the disposition: 0

Shared power to dispose or direct the disposition: 377,264

Flynn is the managing member of the general partner of each of Deerfield Mgmt, Deerfield Mgmt III, Deerfield Mgmt HIF and Deerfield Management. Deerfield Mgmt III is the general partner of Deerfield Private Design Fund III; Deerfield Mgmt HIF is the general partner of Deerfield Healthcare Innovations Fund and Deerfield Mgmt is the general partner of Deerfield Partners. Deerfield Management is the investment manager of the Funds.

(c) No Reporting Person has effected any transactions in the Common Stock during the past sixty days.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: March 27, 2023

DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner

By:	/s/ Jonathan Isler
Name:	Jonathan Isler
Title:	Attorney-in-Fact

DEERFIELD PRIVATE DESIGN FUND III, L.P. By: Deerfield Mgmt III, L.P., General Partner By: J.E. Flynn Capital III, LLC, General Partner

By:	/s/ Jonathan Isler

Name: Jonathan Isler Title:

Attorney-in-Fact

DEERFIELD MGMT HIF, L.P. By: J.E. Flynn Capital HIF, LLC, General Partner

By: /s/ Jonathan Isler Jonathan Isler, Attorney-In-Fact

DEERFIELD HEALTHCARE INNOVATIONS FUND, L.P.

By: Deerfield Mgmt HIF, L.P., General Partner

By: J.E. Flynn Capital HIF, LLC, General Partner

/s/ Jonathan Isler By: Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Name: Jonathan Isler Title: Attorney-in-Fact

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler Name: Jonathan Isler

Title: Attorney-in-Fact

DEERFIELD MANAGEMENT COMPANY, L.P. By: Flynn Management LLC, General Partner

By:	/s/ Jonathan Isler
Name:	Jonathan Isler
Title:	Attorney-in-Fact

JAMES E. FLYNN

/s/ Jonathan Isler Jonathan Isler, Attorney-in-Fact